| Patent Name：2,3,3-Trimethyl-3H-indole |
| Country：[CN] |
Patent ID：[2,3,3-Trimethyl-3H-indole] |
| Remarks： |
Yellow liquid boiling point : 227 ~ 229 ° C 98%
|
|
| Details |
| Patent Name：2,3,3-Trimethyl-4,5-benzo-3H-indole |
| Country：[CN] |
Patent ID：[2,3,3-Trimethyl-4,5-benzo-3H-indole] |
| Remarks： |
Class white crystalline powder, melting point : 107 ~ 110 ° C 98%
|
|
| Details |
| Patent Name：2,3-Dimethyl benzylbromide |
| Country：[CN] |
Patent ID：[2,3-Dimethyl benzylbromide] |
| Remarks： |
Light yellow liquid or crystalline melting point : 40 ~ 42 ° C 98%
|
|
| Details |
| Patent Name：Catalytic hydrogenation of biochemically derived 1,3-propanediol for color reduction |
| Country：[US] |
Patent ID：[US 7211699] |
| Remarks： |
A catalytic hydrogenation process is described for removing impurities and controlling acid for use in downstream processing of biochem. derived 1,3-propanediol by contacting it with hydrogen in the presence of a hydrogenation catalyst (e.g., Raney Ni). The biochem. derived 1,3-propanediol, before the contacting, has an initial color and, after the hydrogenation, has a color that is lower than the initial color. |
|
| Details |
| Patent Name：Convert n-butane to styrene in two reactors |
| Country：[DE] |
Patent ID：[US 7193121] |
| Remarks： |
A method for producing 4-vinylcyclohexene is described comprising: (A) a feed gas stream contg. n-butane is prepd.; (B) the feed gas stream contg. n-butane is fed to at least one dehydrogenation zone, where it is dehydrogenated into butadiene, as well as by products comprising 1-butene, 2-butenes, and optionally steam; (C) the product stream from the dehydrogenation, optionally after sepn. of the steam and minor constituents, is fed into a dimerization zone where the butadiene is catalytically dimerized into a mixt. contg. 4-vinylcyclohexene, n-butane and optionally 1-butene, 2-butene and a product stream contg. butadiene that has not been converted; (D) the 4-vinylcyclohexene from the dimerization product stream is sepd. and the n-butane and optionally 1-butene, 2-butene and the butadiene that has not been converted are returned to the dehydrogenation zone. The 4-vinylcyclohexene product can be dehydrogenated into ethylbenzene or, in the presence of oxygen, oxidatively dehydrogenated into styrene; process flow diagrams are presented. |
|
| Details |
| Patent Name：Methanol- and ethanol-to-olefins is a new twist on ethylene and propylene production |
| Country：[US] |
Patent ID：[US 7196239] |
| Remarks： |
A process for producing light olefins comprises: (A) contacting syngas in the presence of one or more metal-contg. catalysts to produce a first feedstock comprising methanol; (B) converting a portion of the methanol in a homologation zone into a second feedstock comprising ethanol; and (C) introducing the first feedstock and the second feedstock into a process for converting the methanol and the ethanol in the presence of a zeolitic mol. sieve catalyst compn. into light olefins (e.g., ethylene and propylene). Process flow diagrams are presented. |
|
| Details |
| Patent Name：Herbal extracts show promise as COX-2 inhibitors |
| Country：[US] |
Patent ID：[US 7192611] |
| Remarks： |
The invention provides a method for inhibiting COX-2. The method comprises administering a compn. contg. a free-B-ring flavonoid or a compn. contg. a mixt. of free-B-ring flavonoids to a host in need thereof. The invention also includes methods for the prevention and treatment of COX-2-mediated diseases and conditions. The method for preventing and treating COX-2-mediated diseases and conditions comprises administering to a host in need thereof an effective amt. of a compn. contg. a free-B-ring flavonoid or a compn. contg. a mixt. of free-B-ring flavonoids and a pharmaceutically acceptable carrier. |
|
| Details |
| Patent Name：Metallocenes containing ligands of 2-substituted indenyl derivatives, process for their preparation, and their use as catalysts |
| Country：[US] |
Patent ID：[RE39 561] |
| Remarks： |
Abstract
The novel metallocenes of the formula I ##STR00001## in which, preferably, M.sup.1 is Zr or Hf, R.sup.1 and R.sup.2 are alkyl or halogen, R.sup.3 and R.sup.4 are hydrogen, R.sup.5 and R.sup.6 are alkyl or haloalkyl, --(CR.sup.8R.sup.9).sub.m--R.sup.7--(CR.sup.8R.sup.9).sub.n-- is a single- or multi-membered chain in which R.sup.7 may also be a (substituted) hetero atom, m+n is zero or 1, and R.sup.10 is hydrogen, form, together with aluminoxanes as cocatalysts, a very effective catalyst system for the preparation of polyolefins of high stereospecificity and high melting point.
Inventors: Winter; Andreas (Neuleiningen, DE), Antberg; Martin (Hofheim am Taunus, DE), Spaleck; Walter (Bremen, DE), Rohrmann; Ju (Kelkheim, DE), Dolle; Volker (Bensheim, DE)
Assignee: Basell Polyoefine GmbH (DE)
Appl. No.: 08/895,950
Filed: July 17, 1997 |
|
| Details |
| Patent Name：Method for identifying metastatic sequences |
| Country：[US] |
Patent ID：[USRE38392] |
| Remarks： |
Abstract: The invention relates to methods for the identification of metastatic sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to metastasis. Treated cells are implanted in an animal .[.of. ]. .Iadd.at .Iaddend.a primary site and incubated for a period of time sufficient for the cells to proliferate and develop metastases at secondary sites. Expressed sequences from cells at the primary and secondary sites are amplified by differential display polymerase chain reaction and compared. Differentially expressed sequences are . [.identical.]. .Iadd.identified .Iaddend.and can be cloned and sequenced. These sequences can be used as probes in the diagnosis of metastatic disorders, as probes to isolate metastatic sequences and as a therapeutic agent. |
|
| Details |
| Patent Name：Methods of preparing and purifying 9-nitro-20-camptothecin |
| Country：[US] |
Patent ID：[USRE38408] |
| Remarks： |
A method is disclosed for the preparation of 9-nitrocamptothecin which involves reacting 20-camptothecin with at least one inorganic nitrate salt and at least one acid effective in catalyzing the formation of a nitronium ion, where the reaction occurs at a temperature and for a time sufficient to form the 9-nitrocamptothecin. Also, methods of further purifying the 9-nitrocamptothecin by column chromatography or by reprecipitation is also disclosed. |
|
| Details |
